Boston Scientific Corp
BSX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$28.00 | Flfxbp | Mtxwgmbj |
Boston Scientific Sees Farapulse Gain Strength in Its Early Days
Business Strategy and Outlook
Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a prolonged period of operational and management upheaval from 2006 to 2014 wasn't enough to permanently impair Boston's underlying business or the organization's ability to develop and commercialize new technology platforms. Under CEO Michael Mahoney, the firm has focused on introducing novel technology and leveraging its historically formidable sales and marketing resources.